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BACKGROUND AND PURPOSE
Drug interference with normal hERG protein trafficking substantially reduces the channel density in the plasma membrane
and thereby poses an arrhythmic threat. The chemical substructures important for hERG trafficking inhibition were
investigated using pentamidine as a model drug. Furthermore, the relationship between acute ion channel block and
correction of trafficking by dofetilide was studied.
EXPERIMENTAL APPROACH
hERG and KIR2.1 trafficking in HEK293 cells was evaluated by Western blot and immunofluorescence microscopy after
treatment with pentamidine and six pentamidine analogues, and correction with dofetilide and four dofetilide analogues that
displayed different abilities to inhibit IKr. Molecular dynamics simulations were used to address mode, number and type of
interactions between hERG and dofetilide analogues.
KEY RESULTS
Structural modifications of pentamidine differentially affected plasma membrane levels of hERG and KIR2.1. Modification of the
phenyl ring or substituents directly attached to it had the largest effect, affirming the importance of these chemical residues
in ion channel binding. PA-4 had the mildest effects on both ion channels. Dofetilide corrected pentamidine-induced hERG,
but not KIR2.1 trafficking defects. Dofetilide analogues that displayed high channel affinity, mediated by pi-pi stacks and
hydrophobic interactions, also restored hERG protein levels, whereas analogues with low affinity were ineffective.
CONCLUSIONS AND IMPLICATIONS
Drug-induced trafficking defects can be minimized if certain chemical features are avoided or ‘synthesized out’; this could
influence the design and development of future drugs. Further analysis of such features in hERG trafficking correctors may
facilitate the design of a non-blocking corrector for trafficking defective hERG proteins in both congenital and acquired LQTS.
Abbreviations
ER, endoplasmic reticulum; hERG, human ether-a-go-go-related gene; IK1, cardiac inward rectifying K+ current; IKr, rapid
component of the delayed rectifier K+ current; LQTS, long QT syndrome; MD, molecular dynamics; TdP, Torsade de
Pointes
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Introduction
The rapid component of the delayed rectifier K+ current (IKr)
plays a major role in cardiomyocyte repolarization. The
current is carried by pore-forming α-subunits encoded
by the human ether-a-go-go-related gene (hERG or KCNH2)
(Warmke and Ganetzky, 1994; Sanguinetti and Tristani-
Firouzi, 2006). Gene mutations and accompanying hERG
(Kv11.1) channel current reduction (Curran et al., 1995), or a
gain of function mechanism leading to loss of K+ selectivity
and inward rectification (Lees-Miller et al., 2000b) have been
linked to human hereditary long QT syndrome (LQTS),
which is characterized by a prolonged QT interval on the
ECG and an increased risk of sudden cardiac death due to
potentially life-threatening Torsade de Pointes (TdP) arrhyth-
mias (Dessertenne, 1966). The acquired form of LQTS
can arise as a result of antiarrhythmic drug therapy or as a
rare unintended side effect of structurally diverse medica-
tions, such as pentamidine, cisapride, terfenadine or sertin-
dole (Thomsen et al., 2003; Kannankeril et al., 2010).
Consequently, hERG blockade, QT prolongation and pro-
arrhythmia have become an important component of
cardiac safety screening of new pharmacological entities
(Haverkamp et al., 2000; Fenichel et al., 2004). The list of
(potentially) pro-arrhythmic compounds is still growing
and consists mainly of IKr blockers (Haverkamp et al., 2000;
Roden and Viswanathan, 2005) (up-to-date list: http://
www.torsades.org).
For years, malfunctioning of the hERG channel was pre-
sumed to be mainly caused by mutations or drugs that inter-
fered with normal ion conduction, leading to a loss of ion
channel function. However, more recently, an entirely differ-
ent mechanism has been postulated; disruption of normal
ion channel trafficking can lead to severely reduced func-
tional protein levels at the plasma membrane, thereby posing
an arrhythmic threat. The process of trafficking comprises
both anterograde (forward transport towards the plasma
membrane) and retrograde (internalization from the plasma
membrane) transport of ion channel proteins. Loss of hERG
channel function in type 2 LQTS (LQTS2) has been shown to
be caused by different mechanisms; mutations result in chan-
nels that either gate abnormally, are retained in the endoplas-
mic reticulum (ER) due to abnormal intracellular processing,
or are non-functional (Zhou et al., 1998). Remarkably, it has
been shown more recently that the majority of the mutations
found in LQTS2 lead to a trafficking defective hERG channel
that is trapped in the ER (Anderson et al., 2006). Similarly, a
growing number of drugs have been shown to interfere with
normal hERG protein trafficking, thereby reducing the
number of channels in the cell membrane (van der Heyden
et al., 2008). Of note, this chronic drug effect is not detected
in conventional cardiac safety screening, and can thus pose a
potential arrhythmic threat.
The antiprotozoal agent pentamidine has been known to
cause QT prolongation and TdP when used clinically (Jha,
1983; Wharton et al., 1987; Bibler et al., 1988; Girgis et al.,
1997). It severely reduces hERG cell surface expression
without interfering with ion conduction (Cordes et al., 2005;
Kuryshev et al., 2005), acutely blocks the IK1 current, and
interferes with normal KIR2.1 protein expression (de Boer
et al., 2010; Nalos et al., 2011). Recently, it was shown that
pentamidine inhibits hERG ER exit and consequently matu-
ration; an effect that can be corrected by application of the
class III agent astemizole (Dennis et al., 2012). Interestingly,
several trafficking deficient LQTS2 mutants can also be
rescued by application of class III agents (Balijepalli et al.,
2010).
Currently, it is not known which chemical substructures
are responsible for drug-induced hERG trafficking inhibition
or the restoration of both acquired and inherited LQTS.
Therefore, we aimed to (i) determine the chemical features
within pentamidine that are important for acquired traffick-
ing defects, (ii) determine whether dofetilide can restore the
acquired trafficking defects of hERG and KIR2.1, and (iii)
determine the relationship between acute ion channel block
and correction of trafficking. We found that structural modi-
fications of pentamidine differentially affect hERG and/or
KIR2.1 trafficking. Dofetilide and its analogues corrected
pentamidine-induced hERG trafficking defects and this effect
was found to be dependent on their affinity for the channel.
Methods
Animal experiments
Animal care and handling was performed in accordance with
the ‘European Directive for the Protection of Vertebrate
animals used for Experimental and Scientific Purpose, Euro-
pean Community Directive 86/609/CEE’. All experiments
were approved by the Committee for Experiments on
Animals of the Utrecht University, The Netherlands. Three
adult purpose-bred mongrel dogs (Marshall, North Rose, NY,
USA) were used. General anaesthesia was induced by pento-
barbital (25 mg·kg−1 i.v.) and maintained by isoflurane (1.5%
in O2 : NO2 1:2). Atrioventricular block was induced by radi-
ofrequency ablation in all dogs, and ventricular activation
was controlled using a DDDR pacemaker (Vitatron, Arnhem,
The Netherlands). Detailed descriptions of procedures, pacing
protocols and data analysis were published previously
(Winckels et al., 2007). After a minimum of 4 weeks (4–6
weeks), pentamidine (10 mg·kg−1 for 60 min, i.v) was admin-
istered under full anaesthesia. Standard six-lead ECG record-
ings were made regularly over a period of 6 weeks to
determine the long-term electrophysiological effects of pen-
tamidine. All studies involving animals are reported in
accordance with the ARRIVE guidelines for reporting experi-
ments involving animals (Kilkenny et al., 2010; McGrath
et al., 2010).
Cell culture
HEK-293 cells stably expressing GFP-tagged murine wildtype
KIR2.1 (HEK-KWGF) were generated as described previously
(de Boer et al., 2006). HEK-hERG cells were obtained from C.
January (Zhou et al., 1998). Cells were maintained in DMEM
supplemented with 10% fetal calf serum, 2 mM l-glutamine,
50 U·mL−1 penicillin, and 50 μg·mL−1 streptomycin (Verviers,
Belgium). For experiments cells were seeded and incubated in
complete DMEM containing different drugs at various con-
centrations as indicated. Variable incubation times were
achieved by replacing control medium with drug-containing
medium at appropriate time points. During the experiments,
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drug-containing medium was refreshed every 24 h. The
amount of DMSO added to the cells was kept below 0.01%.
Chemical compounds
Pentamidine-isethionate (Pentacrit® 300, Sanofi Aventis,
Gouda, The Netherlands) was dissolved in water at a concen-
tration of 0.1 M, sterilized by filtration (22 μM), aliquoted and
stored at −20°C until further use. Pentamidine analogues (PAs;
see Table 1, PA-1 to PA-7) were synthesized as described pre-
viously (Jones et al., 1990; Tidwell et al., 1990; Bakunova et al.,
2009a,b), and were dissolved in water (PA-1 to PA-5) or DMSO
(PA-7) at the highest concentration possible (≤25 mM). Dofe-
tilide and its analogues were dissolved in DMSO at a concen-
tration of 10 mM. Dofetilide analogues (DA) were synthesized
as described previously (Shagufta et al., 2009).
Western blot
Cell lysates were prepared in buffer D (20 mM HEPES,
125 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothrei-
tol, 10% glycerol, and 1% Triton X-100) supplemented with
1 mM PMSF and 6.8 μg·mL−1 aprotinin (Sigma-Aldrich,
Zwijndrecht, The Netherlands). Fifteen micrograms of
protein lysate was mixed with Laemmli sample buffer,
separated by 7% (hERG) or 10% (KIR2.1) SDS-PAGE and sub-
sequently electroblotted onto a nitrocellulose membrane
(Biorad, Veenendaal, The Netherlands). Reversible Ponceau
staining was used to reveal equal protein loading and subse-
quent quantification. KIR2.1-GFP was detected by monoclonal
anti-GFP (cat. no. Sc-9996; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), hERG protein was detected by polyclonal
anti-hKv11.1 primary antibody (cat. no. APC-062; Alomone
Labs, Jerusalem, Israel). Peroxidase-conjugated secondary
antibodies were used to facilitate final detection with a stand-
ard ECL procedure (Santa Cruz Biotechnology).
Immunofluorescence microscopy
HEK-hERG cells were cultured on poly-l-lysine (Sigma)-
coated 15 Ø glass cover slips (Smethwick, Warley, UK),
Table 1
Chemical structures of pentamidine (P) and dofetilide (D) and their derivatives used in this study
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fixated with 3% paraformaldehyde dissolved in PBS. Cells
were quenched with 50 mM glycine-PBS after permeabi-
lization with 0.5% Triton X-100, and subsequently blocked
with NET-gel (150 mM NaCl, 5 mM EDTA, 50 mM Tris-HCl,
pH 7.4, 0.05% igepal, 0.25% gelatin, 0.02% NaN3). Cells
were then incubated overnight with polyclonal anti-
hKv11.1 primary antibody (cat. no. APC-062; Alomone
Labs), followed by incubation with anti-rabbit FITC-
conjugated secondary antibody (Jackson ImmunoResearch)
for 2 h. Covers slips were mounted with Vectashield
(Vector Laboratories Inc., Burlingame, CA, USA), and con-
focal images were obtained using a Zeiss Axiovert 200 M
confocal microscope (Carl Zeiss Microscopy GmbH, Jena,
Germany) equipped with a ×40 water immersion objective
(NA 1.2) plus ×2 digital zoom. Excitation was performed
with an air-cooled argon ion laser (LASOS, RMC 7812Z,
488 nm).
Drug docking and molecular dynamics
(MD) simulations
Docking was performed with the program Gold 4.0.1 (GOLD,
2008) using the Gold scoring functions. The recently pub-
lished hERG homology model termed ‘model 6’ (Stary et al.,
2010) after 50 ns MD simulations was used as a template for
docking. Coordinates of the geometric centre calculated
among the Y652 and F656 residues were taken as binding site.
The binding site radius was set to 10 Å. The 10 best-ranked
poses of each docking run were used for visual analysis. The
most frequent binding mode was used as a starting confor-
mation for MD simulations.
MD simulations were performed with Gromacs v. 4.5.4.
(Hess et al., 2008) as described previously (Knape et al., 2011).
Briefly, the hERG model was embedded in an equilibrated
membrane consisting of 280 dioleolylphosphatidylcholine
(DOPC) lipids by making use of the g_membed tool (Wolf
et al., 2010). The amber99sb force field (Hornak et al., 2006)
with lipid parameters taken from Siu et al. (2008), and the
TIP3P water model (Jorgensen et al., 1983) were utilized.
Geometry optimization and topology generation of the drugs
was carried out with HF/3-21G, implemented in Gaussian09
(Frisch et al., 2009) and antechamber (Case et al., 2010)
respectively. Prior to simulations, 1000 conjugate gra-
dient energy-minimization steps were performed. Subse-
quently, the systems were equilibrated for 1 ns for each
docked compound. During equilibration, the protein
and the ligand were restrained with a force constant of
1000 kJ·mol·nm−2, while the lipids, the ions, and the water
were allowed to move freely. Each drug was simulated for
50 ns.
Statistics
Group averages are presented as mean ± SEM, unless indi-
cated otherwise. Differences between groups were tested
using one-way ANOVA with a Bonferroni post hoc test. A
statistically significant difference was considered if P < 0.05.
All analyses were carried out using SPSS (SPSS 19.0 IBM,
Armonk, NY, USA).
Drugs and molecular target nomenclature conform to the
British Journal of Pharmacology’s Guide to Receptors and Chan-
nels (Alexander et al., 2011).
Results
A single dose of pentamidine lengthens the
QT interval
The time course of QT interval changes after a single dose
of pentamidine is summarized in Figure 1. The QT interval
did not change during and directly after pentamidine admin-
istration in any of the three dogs. After 7 days, the QT inter-
val prolongs progressively, which persists until day 21,
demonstrating the typical chronic effect of pentamidine on
repolarization.
Pentamidine and its analogues differentially
inhibit hERG and/or KIR2.1 trafficking
Pentamidine inhibited anterograde hERG trafficking, as can
be seen in Figure 2A. The mature protein level (upper band)
was severely reduced compared with control levels after 48 h
treatment with 10 μM pentamidine (0.2 ± 0.02 vs. 1.0 ± 0.0, P
< 0.05). In addition, KIR2.1 protein levels were also analysed.
As expected, 10 μM pentamidine for 48 h significantly
decreased KIR2.1 protein levels compared with control
(Figure 2B). At present, the chemical characteristics and sub-
structures within trafficking inhibiting drugs that specifically
interfere with the normal trafficking process of these potas-
sium ion channels have not been identified. To identify
potentially trafficking inhibiting substructures, pentamidine
was used as a model drug, and several analogues were tested
for ion channel trafficking inhibiting capacity. The molecular
structure of pentamidine is depicted in Table 1. Compared
with the lead compound, PA-1, 2 and 3 contain modifications
in the linker between the benzamidine groups, PA-4 has pyri-
dine instead of phenyl rings, and PA-5 and 7 contain substi-
tuted benzamidine moieties (Table 1).
Both HEK-hERG and HEK-KWGF cells were treated with
10 μM pentamidine or its analogues for 48 h (Figure 2). Com-
Figure 1
Electrophysiological effects of 10 mg·kg−1 pentamidine over 60 min
in AV-blocked dogs paced from the high septum. A delayed effect of
pentamidine on the QT interval was observed. QT prolongation
became apparent 4 days after i.v. pentamidine administration that
persisted for 17 days, after which the prolongation dissipated gradu-
ally. Data are presented as mean ± SD (n = 3).
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pared with pentamidine, either shortening or lengthening
the carbon linker between the aromatic rings had slight
effects on hERG protein maturation. PA-1 was a slightly less
effective trafficking inhibitor (0.30 ± 0.03 vs. P 0.20 ± 0.02,
ns), while PA-2 was slightly more potent than pentamidine
(0.15 ± 0.02 vs. P 0.20 ± 0.02, ns). Interestingly, substitution
of the oxygen directly attached to the aromatic residues by
sulphur considerably increased hERG trafficking inhibition
Figure 2
Pentamidine and its analogues differentially affect hERG and KIR2.1 protein levels. (A) Western blot showing the effects of pentamidine or its
structural analogues (10 μM, 48 h) on hERG forward trafficking (n = 12 for control and pentamidine, n = 3 for PA-4, n = 4 for all other analogues).
(B) Western blot showing the effects of pentamidine or its structural analogues (10 μM, 48 h) on KIR2.1 protein expression (n = 3 for PA-4 and 7,
n = 4 for control, pentamidine, and all other analogues). Total protein staining (Ponceau) was used as a loading control. Control protein levels
(untreated cells) were designated as 100% after correction; *indicates P < 0.05 versus control, ‡indicates P < 0.05 versus pentamidine treatment.
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(PA-3 0.04 ± 0.02 vs. P, PA-1, PA-4, PA-5, or PA-7, P < 0.05). In
contrast, PA-5 (P < 0.05 vs. P, and PA-2, 3, 4) and PA-7 (P < 0.05
vs. P, and PA-2, 3, 4) were significantly less potent than
pentamidine, although protein levels comparable with
control were not reached. PA-4 – in which the phenyl rings
are replaced by pyridine – was the least potent hERG traffick-
ing inhibiting compound (P < 0.05 for PA-4 vs. P and PA-1 to
7). Although control protein levels were not reached, mature
hERG protein levels were substantially increased when PA-4
and pentamidine treatment were compared (Figure 2A). All
these data indicate that an unaltered amidine substituent and
the nature of the aromatic rings are important determinants
of the interaction of pentamidine and the hERG channel
during the trafficking process. It should be kept in mind
though, that the compounds were tested at one concentra-
tion only, and that full concentration–response curves would
allow a more definitive and quantitative SAR analysis.
In accordance with their effect on hERG trafficking, the
effect of PA-1 and 2 on KIR2.1 protein levels differed slightly
when compared with pentamidine (Figure 2B). In contrast,
PA-4, 5 and 7 hardy affected KIR2.1 protein levels. Interest-
ingly, PA-4 also slightly affected hERG trafficking. When com-
paring the effects of the pentamidine analogues on hERG and
KIR2.1, the differential effect of PA-3 on these proteins repre-
sents an obvious discrepancy. While hERG trafficking was
severely inhibited, KIR2.1 protein levels were hardly affected
(0.90 ± 0.2 vs. control 1.0 ± 0.0, ns), which could imply that
the mechanism by which pentamidine inhibits trafficking
differs between these ion channels.
Dofetilide rescues pentamidine-induced hERG,
but not KIR2.1, trafficking defects
In order to reduce the pentamidine-induced hERG channel
trafficking block, we applied the high affinity class III agent
dofetilide in different concentrations to HEK-hERG cells in
the continuous presence of 10 μM pentamidine. Application
of even 0.03 μM dofetilide significantly increased mature
hERG levels compared with pentamidine (0.7 ± 0.1 vs. 0.3 ±
0.03, P < 0.05, Figure 3A), and at a concentration of 1 μM,
dofetilide completely restored anterograde hERG trafficking.
Interestingly, higher concentrations of dofetilide seemed to
increase hERG trafficking efficiency, since significantly higher
mature protein levels were reached compared with control
levels.
The timeframe in which the pharmacological correction
of drug-induced trafficking was taking place is unknown.
Therefore, HEK-hERG cells were first exposed to pentamidine
(10 μM) for 48 h; subsequently, dofetilide (1 μM) was added
in the continued presence of pentamidine and mature
protein levels were determined after different incubation
times. Mature protein levels increased time- dependently, and
were completely restored after 4–6 h of dofetilide treatment
(Figure 3B). This timeframe strongly suggests that the correc-
tion of pentamidine-induced trafficking defects occurred
post-transcriptionally, most likely via the relief of ER
retention.
Since dofetilide is a high affinity class III agent, we
hypothesized that its correction of ion channel trafficking
defects could be ion channel-specific, and the pharmacologi-
cal chaperone used has to bind directly to the particular ion
channel involved. To test this hypothesis, we evaluated
whether pentamidine-affected KIR2.1 protein levels could be
corrected by application of dofetilide. As expected, treatment
with dofetilide up to 30 μM did not restore KIR2.1 protein
levels (0.4 ± 0.06 vs. P 0.25 ± 0.05, ns, n = 3, Figure 3C).
Correction of pentamidine-induced hERG
trafficking defects depends on an affinity
for the channel
Since dofetilide has a high affinity for the hERG channel and
specifically restores drug-induced hERG trafficking defects,
we wondered which substructures that affect channel affinity
are important in the molecule. The structure of dofetilide is
depicted in Table 1; its protonated tertiary nitrogen, phenyl
rings and methanesulphonamide substituents are known to
be important for high affinity binding (Shagufta et al., 2009).
Furthermore, the spacing between the central basic nitrogen
and the aromatic residues might also be of significance for
efficient binding (Pearlstein et al., 2003). In all the dofetilide
analogues (DA) used in this study, the methanesulphonamide
substituent was replaced; in DA-2 by –NH2, in DA-1, 3 and 4
by NO2 groups. In addition, DA-3 was differently substituted
at the central nitrogen, and in DA-4, the length of the chain
connecting the two phenyl groups was modified. DA-1 was
used as a reference compound for synthesis of DA-3 and 4.
Compared with dofetilide (Ki 4.9 ± 0.9 nM), DA-1 had a
comparable affinity (Ki 5.7 ± 3.0 nM) for the hERG channel,
DA-3 and 4 had moderate affinity (Ki 278 ± 73 nM and Ki 202
± 4.9 nM), and DA-2 had a very low affinity (Ki > 10 μM) for
the channel (Shagufta et al., 2009).
Dofetilide and the four analogues were tested for their
ability to correct drug-induced trafficking defects (Figure 4A).
DA-1, in which a nitro-substituent replaces the methanesul-
phonamide group, was almost as effective as dofetilide. In
contrast, substitution with a polar NH2 group (DA-2) com-
pletely abolished the trafficking correction capacity (30 μM
DA-2 0.40 ± 0.04 vs. control 1.0 ± 0.0, P < 0.05; 30 μM DA-2
0.40 ± 0.04 vs. 30 μM dofetilide 1.9 ± 0.4, P < 0.05) in asso-
ciation with a substantial decrease in hERG binding affinity
(Shagufta et al., 2009). In DA-3, the basicity of the central
nitrogen was abolished by acylation; as a consequence, not
only was hERG affinity decreased considerably, but also hERG
trafficking defects were only partially corrected (30 μM DA-3
0.60 ± 0.1 vs. control 1.0 ± 0.0, P < 0.05; 30 μM DA-3 0.60 ±
0.1 vs. 30 μM dofetilide 1.9 ± 0.4, P < 0.05). DA-4, which had
a moderate hERG affinity due to a variation in chain length,
also partially corrected the pentamidine-induced trafficking
defect. It remains puzzling, however, why higher concentra-
tions of the lower-affinity compounds DA-3 and DA-4 do not
fully restore mature protein levels.
The subcellular localization of the hERG protein after
trafficking inhibition with pentamidine and correction
thereof with dofetilide and its analogues (1 μM) was studied
by immunofluorescence staining of hERG (Figure 4B). In
untreated control cells, hERG was distributed throughout the
cell and clear membrane staining was detected, as was the
case after only dofetilide treatment. As expected, membrane
staining was lost after pentamidine treatment, and intracel-
lular staining had a more restricted perinuclear pattern. The
localization of the hERG protein after application of the cor-
rectors correlated with their efficacy and was in agreement
with the results of the Western blots. Correction of
BJPIon channel trafficking
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Figure 3
Dofetilide corrects pentamidine-induced hERG trafficking defects. (A) Western blot showing the concentration-dependent correction of hERG
protein levels in the presence of pentamidine. Dofetilide 1 μM completely restored mature hERG protein levels, higher concentrations increased
mature hERG protein levels even further (n = 24 for control and pentamidine, n = 6 for all dofetilide concentrations). (B) Dofetilide time-
dependently corrects mature hERG protein levels. Treatment of pentamidine-exposed (10 μM, 48 h) HEK-hERG cells with 1 μM dofetilide restored
mature hERG levels within 4–6 h (n = 24 for control and pentamidine, n = 3 dofetilide). (C) In contrast to the beneficial effect on hERG trafficking,
pentamidine-mediated downregulation of KIR2.1 could not be corrected by application of dofetilide (n = 3 for all conditions). Total protein staining
(Ponceau) was used as a loading control. Control protein levels (untreated cells) were designated as 100% after correction; *indicates P < 0.05
versus control, ‡indicates P < 0.05 versus pentamidine treatment.
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pentamidine-induced trafficking defects with dofetilide or
DA-1 revealed a pattern comparable with control cells, as
both compounds completely restored mature hERG protein
levels. In contrast, DA-2- treated cells displayed a staining
similar to cells treated with pentamidine alone. After treat-
ment with DA-3 or DA-4, which are both partial correctors,
the hERG protein was scattered throughout the cell but
membrane staining was considerably less when compared to
control cells.
Finally, to gain further insight in the relationship between
drug binding affinity and correction of hERG trafficking
defects, drug docking and molecular dynamic simulations
were performed. All dofetilide derivatives in our hERG model
displayed considerable stability during the course of 50 ns MD
Figure 4
Correction of pentamidine-induced hERG trafficking defects is influenced by structural modifications of dofetilide (A). Compared with dofetilide,
the high affinity analogue DA-1 was an equally effective corrector, while the other analogues were significantly less effective when tested at 1 μM
(n = 24 for control and pentamidine, n = 6 for dofetilide, n = 3 for DA-1 and 2, n = 5 for DA-3 and 4). Total protein staining (Ponceau) was used
as a loading control. Control protein levels (untreated cells) were designated as 100% after correction; *indicates P < 0.05 versus control, ‡indicates
P < 0.05 versus pentamidine treatment. (B) In control conditions, the hERG protein is present in the cytoplasm and at the plasma membrane. A
similar staining pattern was seen after only dofetilide treatment. After pentamidine treatment, only cytoplasmic staining was apparent. Staining
patterns after correction of these effects with dofetilide or its structural analogues were in agreement with the Western blot results; effective
correction showed hERG staining both at the plasma membrane and intracellularly, while ineffective correctors showed only intracellular staining.
The hERG protein is shown in green.
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simulations. Key interactions, involving Y652 and F656, are
shown in Figure 5. The numbers of hydrophobic and aromatic
interactions a compound has (Table 2) are in good agreement
with its ability to correct pentamidine-induced trafficking
defects. While the compounds dofetilide and DA-1
(Figure 5A–D) had a large number of favourable interactions,
DA-2, DA-3 and DA-4 had very few interactions with the
hERG model. Our modelling studies suggest that dofetilide
and DA-1 stabilize the hERG structure via pi-pi stacking, while
the low affinity compound DA-2 cannot provide sufficient
stabilizing interactions to correct pentamidine trafficking
defects. DA-3 and DA-4 take an intermediate position between
D and DA-1 on the one, and DA-2 on the other hand.
Discussion
Detrimental drug interactions with the hERG potassium
channel constitute a major pharmacological safety concern
during drug development. In recent years, it has become
recognized that, in addition to hERG current inhibition,
chronic drug effects should also be considered as a potential
safety hazard (van der Heyden et al., 2008), as the dangerous
effects of trafficking inhibiting agents like pentamidine and
arsenic trioxide are not always detected in conventional
hERG safety screening assays (Katchman et al., 2006).
Although ion channel trafficking assays are available (HERG-
Lite® and CHAN-Lite®, ChanTest™, Cleveland, Ohio), they
have not been adopted by the current guidelines. In order to
avoid toxicity, it is imperative to understand the structural
requirements needed not only for hERG binding, but also for
hERG trafficking inhibition, and this would be of great
benefit for the drug design and development process.
Figure 5
MD poses and 2D interaction profiles of dofetilide (A,B), DA-1 (C,D),
DA-2 (E,F), DA-3 (G,H) and DA-4 (I,J). Snapshots after 50 ns are
shown. Binding determinants Y652 and F656 are shown as raspberry
sticks. Drug molecules are coloured orange, with nitrogen atoms
coloured blue, oxygen atoms coloured red and sulfur groups col-
oured yellow. 2D interaction profiles were generated with PoseView
(poseview.zbh.uni-hamburg.de). Green dotted lines indicate pi-pi
interactions between aromatic rings, green solid lines represent
hydrophobic interactions. Hydrogen bonds are shown as black
dotted lines.
▶
Table 2
Number of interactions for dofetilide derivatives
Compound
Σ of hydrophobic IAs
(pi-pi stacking) HB IAs
D 3 (1) –
DA-1 4 (2) –
DA-2 – 1
DA-3 2 (1) –
DA-4 1 (1) –
HB, hydrogen bonds; IAs, interactions.
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At present, it is not known which chemical substructures
in pentamidine are important for selective disruption of
hERG ion channel trafficking. Our results indicate that the
aromatic residues, in particular, are essential, as modifications
of these groups (PA-3 and 4) have a large effect on hERG ion
channel trafficking. PA-4, which had the most favourable
trafficking safety profile, was evaluated in a mouse model
of trypanosomiasis. Unfortunately, the compound was not
effective, although it was well tolerated (Bakunova et al.,
2009b). Interestingly, both PA-3 and 4 mildly affected KIR2.1
density, while PA-3 severely affected hERG maturation. PA-2
had a large effect on both KIR2.1 and hERG density. The
differential effect of these compounds suggests that the
mechanism by which pentamidine exerts protein downregu-
lation differs between these potassium channels. In line with
this, we found that the specific IKr inhibitor dofetilide cor-
rected hERG channel but not KIR2.1 channel density after
pentamidine treatment. Previously, we showed that inhibi-
tion of lysosomal degradation restores KIR2.1 protein levels
in pentamidine-treated HEK-KWGF cells, which strongly
suggests that pentamidine increases KIR2.1 retrograde
trafficking and degradation (Nalos et al., 2011). In addition,
pharmacological interference at different levels in the
clathrin-dependent internalization route and thus retrograde
trafficking, increase pentamidine-affected KIR2.1 protein
levels (Varkevisser et al., 2013).
In the present study, we showed that dofetilide also cor-
rects pentamidine-induced hERG anterograde trafficking
defects and the correction efficacy depends on the com-
pound’s affinity for the channel. A fair agreement between
affinity and correction was observed; a high affinity analogue
(DA-1) completely restored mature hERG protein levels in the
presence of pentamidine while analogues with moderate
(DA-3 and 4) or low affinity (DA-2) restored mature protein
levels partially or not at all. Our results favour the hypothesis
that pentamidine and its correctors compete for the same
binding site within the hERG channel. While pentamidine
supposedly binds to an emerging hERG drug binding site in a
conformation folding intermediate leading to an arrest in
channel maturation (Dennis et al., 2012), displacement by a
high affinity corrector stabilizes the channel, thereby allevi-
ating the block in maturation. However, based on their
chemical structure, it seems unlikely that dofetilide and pen-
tamidine share a common binding site. Alternatively, penta-
midine could bind to a different binding site in the immature
hERG protein, which is not available in the mature protein.
When performing MD simulations with pentamidine, no
consistent interactions between the drug and the hERG
model were found, in contrast to dofetilide and its analogues
(Figure 5). This finding would be consistent with pentami-
dine binding to a channel intermediate instead of the mature
channel. Presumably, pentamidine binding destabilizes the
immature hERG protein, leading to its retention in the ER by
quality control mechanisms; the binding of a high affinity
class III agent at an allosteric site will then stabilize the
immature protein and promote maturation. If this hypothesis
is correct, dofetilide would operate similarly in the presence
of other destabilizing agents. Mutation of amino acid residues
F656 and Y652 that affect pentamidine sensitivity (Dennis
et al., 2012) could, therefore, also have an indirect effect, as a
mutation of these residues can affect the characteristics of the
current (Lees-Miller et al., 2000a; Fernandez et al., 2004;
Kamiya et al., 2006) possibly by small conformational
changes. This could either directly obscure the binding site or
reduce pentamidine binding because of steric hindrance. The
direct hERG block and trafficking inhibition induced by
several other drugs were found to be mediated by the drugs
binding to different sites. Ketoconazole, fluconazole and
fluoxetine, which are all direct IKr blockers, as well as hERG
trafficking inhibitors, do not seem to bind to the canonical
drug binding site in the immature hERG protein, as a muta-
tion of residues Phe656 and Tyr652 abolished the direct IKr block
but had no effect on hERG trafficking inhibition (Rajamani
et al., 2006; Takemasa et al., 2008; Han et al., 2011). Further-
more, application of the high affinity IKr blocker E-4031 did
not restore the hERG trafficking inhibition induced by either
fluoxetine or norfluoxetine (Rajamani et al., 2006).
The mechanism by which pentamidine arrests hERG
channel maturation is not known. It has been suggested that
disruption of the channel–chaperone interactions could play
a role. Wild-type hERG proteins have been shown to interact
with the cystosolic chaperones Hsp70 and Hsp90 and the ER
chaperone calnexin (Ficker et al., 2003; Gong et al., 2006).
Not surprisingly, drugs like geldanamycin and As2O3 that
inhibit Hsp70 and 90, arrested hERG maturation (Ficker et al.,
2003; 2004). However, it should be noted that these drugs
have complex actions and could potentially inhibit the
correct folding of other proteins, including other (cardiac)
ion channels. On the other hand, it has been shown that
pentamidine does not interfere with the actions of Hsp70 or
Hsp90 (Dennis et al., 2012), but it could disrupt the associa-
tion of hERG with other chaperones, like calnexin. Calnexin
associates transiently with wild-type immature hERG chan-
nels for up to 8 h, whereas its association with the trafficking
deficient LQTS2 mutant N470D was prolonged (Gong et al.,
2006). Association times between calnexin and this mutant
channel approached the normal time frame in the presence
of E-4031 and accordingly the protein levels of this mutant
hERG were completely restored within 8 h (Zhou et al., 1999).
In agreement with these findings, we showed that dofetilide
completely restored hERG protein levels within 8 h in the
presence of pentamidine. Further research is needed to eluci-
date the precise mechanism by which pentamidine arrests
hERG maturation.
In several human diseases mutant proteins fold or assem-
ble improperly, resulting in defective protein trafficking
(Cohen and Kelly, 2003). Correction of defective trafficking
by protein-specific modulators or drug substrates was first
shown for misprocessed human P-glycoprotein mutants (Loo
and Clarke, 1997). Using this approach as potential clinical
therapy, great progress has been achieved in the treatment of
cystic fibrosis. A promising small molecule (VX-809) that
corrects anterograde trafficking of ΔF508-CFTR mutant pro-
teins has entered clinical trials (Clancy et al., 2012). Pharma-
cological correctors of either mutant or drug-induced
trafficking deficient hERG channels are typically also direct
hERG channel blockers, and their efficacy appears to be
related to the domain in which the mutation is located and
the affinity of the class III agent used (Ficker et al., 2002;
Balijepalli et al., 2010; Dennis et al., 2012). In agreement with
earlier results in LQTS2 mutants (Ficker et al., 2002), in the
present study, we showed that correction of drug-induced
BJPIon channel trafficking
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hERG trafficking defects is dependent on channel affinity and
is channel specific. In particular, modifications near a com-
pound’s aromatic residues greatly affect its ability to restore
the drug-induced hERG trafficking. Further research into the
difference between direct hERG channel blockade and correc-
tion of defective trafficking is necessary and may be of benefit
for the treatment of defective hERG trafficking.
In conclusion, structural modifications of pentamidine
differentially affected plasma membrane levels of hERG and
KIR2.1. Modification of the phenyl ring or substituents
directly attached to it had the largest effect, highlighting the
importance of these features in ion channel binding. Thus, if
certain residues are avoided or ‘synthesized out’, the ability to
inhibit trafficking can be abolished, as was shown with PA-4,
which had mild effects on both ion channels. Correction of
defective protein trafficking is ion channel-specific and
requires high affinity binding. Further analysis of important
features in other hERG channel trafficking correctors may
facilitate the design of a non-blocking corrector for trafficking
defective hERG proteins in both congenital and acquired
LQTS.
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